Porter C W, Bergeron R J
Grace Cancer Drug Center, Roswell Park Memorial Institute, Buffalo, New York 14263.
Adv Exp Med Biol. 1988;250:677-90. doi: 10.1007/978-1-4684-5637-0_60.
Interference with polyamine biosynthesis by analog-mediated regulatory mechanisms represents a viable alternative to the use of specific enzyme inhibitors as an antiproliferative strategy. The approach is unique among antimetabolite approaches and is made possible by unusual characteristics inherent to the polyamines and their biosynthetic pathway. Current antitumor data obtained with these analogs provides indication of their potential usefulness as antitumor agents but, at the same time, demonstrates the need for improvement. This latter might be attained by the rational design of analogs which (a) bind more tightly at enzyme regulatory sites, (b) which are less able to substitute for natural polyamines in growth related functions and (c) which are eliminated less rapidly from tumor-bearing animals. At the same time, the continued preclinical development of available analogs might proceed most productively by targeting large cell lung carcinoma and melanoma and by examining the generality of the relationship between oncogene expression and the accompanying sensitivity to regulatory analogs.
通过类似物介导的调节机制干扰多胺生物合成,是使用特定酶抑制剂作为抗增殖策略的一种可行替代方法。该方法在抗代谢物方法中独具特色,多胺及其生物合成途径固有的特殊性质使其成为可能。目前使用这些类似物获得的抗肿瘤数据表明它们作为抗肿瘤药物具有潜在用途,但同时也表明需要改进。后者可以通过合理设计类似物来实现,这些类似物要:(a)在酶调节位点结合更紧密;(b)在与生长相关的功能中较难替代天然多胺;(c)从荷瘤动物体内消除速度较慢。同时,现有类似物的临床前开发可以最有效地通过针对大细胞肺癌和黑色素瘤,并研究癌基因表达与对调节类似物的伴随敏感性之间关系的普遍性来进行。